Skip to main content

Recent News

  • ACR
    congress

    On May 7th, the American College of Rheumatology (ACR) hosted its annual Capitol Hill fly-in with rheumatology leaders nationwide to champion the need for crucial reforms to the Medicare Physician Fee Schedule (MPFS). The goal is to enhance the payment system’s predictability and stability, ensuring continued access to care for patients by adequately supporting healthcare providers.

    Read Article

Does Good Sleep Prevent Osteoporosis

EurekAlert!

As part of the University of Colorado Department of Medicine’s annual Research Day, held on April 23, faculty member Christine Swanson, MD, MCR, described her National Institutes of Health-funded clinical research on whether adequate sleep can help prevent osteoporosis.

Read Article
Multiplicative Adverse Effects of Social Determinants of Health in Lupus Nephritis: A Meta-analysis and Systematic Review https://t.co/Wht67skbG2 https://t.co/D55phMfHGh
Dr. John Cush @RheumNow (  View Tweet)
Watch Dr. Anca Askanase and Dr. Ashira Blazer discuss the importance of social determinants of health and equitable care to slow organ damage progression in #Lupus #CaseStudy #SponsoredbyGSKUSMA https://t.co/Ajlqk2g3jj https://t.co/d4YnixOT05
Dr. John Cush @RheumNow (  View Tweet)
Imaging-Only Diagnosis of Giant Cell Arteritis Is Feasible Positive findings with color Doppler ultrasound were enough to diagnose GCA accurately without need for confirmation with TAB, a prospective study indicated. https://t.co/2b3y2OCENA https://t.co/4OOFo1hRCv
Dr. John Cush @RheumNow (  View Tweet)

Pharmacologic Efficacy in Still's Disease

A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.

Read Article

Cutoffs for Systemic Juvenile Arthritis Disease Activity Score

An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10), a disease activity measure distinguish patients with inactive disease, minimal disease activity, moderate disease activity, and high disease activity.

Read Article
Featured BSR Abstracts Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released. https://t.co/Km8alIyCIP https://t.co/8yYUldF0pw
Dr. John Cush @RheumNow (  View Tweet)
Lower Limb Muscle Mass Influences Osteoarthritis Risk The Rotterdam study shows that weight-bearing recreational physical activity caused more incident knee osteoarthritis (KOA), but mainly when there was low muscle mass. https://t.co/N6JnJJgXgY https://t.co/hL7fK0DPWJ
Dr. John Cush @RheumNow (  View Tweet)
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/tuO7UsEfrL https://t.co/KGcdBtneQt
Dr. John Cush @RheumNow (  View Tweet)
French insurance claims study of 12071 #PsA pts on biologics (2015-2021) found total of 367 serious infections (3%; IR 1.7/100PY). SIR risk significantly lower for new users of etanercept (wHR 0.72) & ustekinumab (wHR 0.57) (vs ADA new users https://t.co/CutqoxA05e https://t.co/OUCUbrKnFF
Dr. John Cush @RheumNow (  View Tweet)
Long term F/U of T2T in BeST (early RA 153) & IMPROVED (UA 282) pts 12 & 20 yrs after, the majority of RA & UA pts were in DAS remission (91% LDAS, 68% remission), & w/ limited functional disability (mean HAQ 0.6-0.8). Xray progression was mild https://t.co/vcL8Mnv0Ty https://t.co/lPVbNipFng
Dr. John Cush @RheumNow (  View Tweet)
#BSR Analysis of 1,362 pts starting 1st JAKi before EMA warnings on JAKi (1/23) showed 28% prev failed ≥3 bDMARDs & 80% met ≥1 EMA JAKi risk criteria -that included 1) age ≥65 2) incr CV risk; 3) current/past smoker; 4) prior cancer https://t.co/U3IaswZUyy https://t.co/m43RDAbpwP
Dr. John Cush @RheumNow (  View Tweet)

Multiplicative Adverse Effects of Social Determinants of Health in Lupus Nephritis: A Meta-analysis and Systematic Review

A metanalysis shows that social determinants of health adversely impacts patients with lupus nephritis. Lupus nephritis is a significant complication of SLE, often with dramatic increases in morbid and mortal risks. Outcomes are likely to be augmented by social determinants of health, including socio-economic status, and social risk factors.

Read Article

Imaging-Only Diagnosis of Giant Cell Arteritis Is Feasible

Medpage Today

Positive findings with color Doppler ultrasound were enough to diagnose giant cell arteritis (GCA) accurately without need for confirmation with temporal artery biopsy (TAB), a prospective study indicated.

Read Article
Machine learning analysis of retrosp EHR data (3/20-9/22) on 2+ million showed COVID (5.3%) outcomes in #IMID pts not linked to DMARD or IMID Dx; but rather to age, unvaccinated, & comorbidities (Afib, CAD, CHF, CKD, COPD, CA, liver Dz) https://t.co/aMmJD5P9cc https://t.co/Yy9FuCvol4
Dr. John Cush @RheumNow (  View Tweet)
SLE Faculty Panel Q&A https://t.co/2OWlhfmKaP https://t.co/jx6MPDtojS
Dr. John Cush @RheumNow (  View Tweet)
Complex Autoantibody Patterns in RA https://t.co/WmaXmmP7dY https://t.co/4dFgFEZ84i
Dr. John Cush @RheumNow (  View Tweet)
NEJM: evolution of pyoderma gangrenosum skin lesions https://t.co/vsgQhsjY5q https://t.co/INrbTIc9kX
Dr. John Cush @RheumNow (  View Tweet)
Systemic Inflammation and Mortality in RA-ILD Analysis of the German RABBIT registry shows that systemic inflammation, more so than disease activity, strongly influences all-cause mortality in patients with RA-ILD. https://t.co/Qjtg364Pv7 https://t.co/aTQxTcO6Yv
Dr. John Cush @RheumNow (  View Tweet)
In 530 #GCA pts, relapses seen in 46%; but severe relapse (ischemi/aortic events) in 3%. Severe GCA relapse pts more likely to be younger at Dx(P=0.02), w/ more limb claudication(< 0.0001), fewer GCA-related cranial Sxs (<0.0001); but not higher mortality https://t.co/k7wgU6oMcn https://t.co/BKOfGmZ27u
Dr. John Cush @RheumNow (  View Tweet)